Comparison of Systemic Treatments for Metastatic Castration-Sensitive Prostate Cancer
Authors:
Open Access
- 1 March 2021
- journal article
- review article
- Published by American Medical Association (AMA) in JAMA Oncology
- Vol. 7 (3) , 412-420
Abstract
Prostate cancer is the most common cancer and the second leading cause of cancer death among men in the US.1 Quiz Ref ID Although 76% of the patients with prostate cancer were first diagnosed with localized cancer,2 approximately 30% of these patients experience disease recurrence after definitive treatments.3 Most recurrent prostate cancers initially respond to androgen-deprivation therapy (ADT) but eventually develop resistance, transforming from castration-sensitive to castration-resistant prostate cancer.4 Metastatic castration-resistant prostate cancer is associated with high mortality: a 5-year survival rate of 30%.2Keywords
This publication has 36 references indexed in Scilit:
- Androgen Deprivation Therapy (ADT) Plus Docetaxel Versus ADT Alone in Metastatic Non castrate Prostate Cancer: Impact of Metastatic Burden and Long-term Survival Analysis of the Randomized Phase 3 GETUG-AFU15 TrialEuropean Urology, 2016
- Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trialThe Lancet, 2016
- Automated generation of node‐splitting models for assessment of inconsistency in network meta‐analysisResearch Synthesis Methods, 2015
- Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate CancerNew England Journal of Medicine, 2015
- The PRISMA Extension Statement for Reporting of Systematic Reviews Incorporating Network Meta-analyses of Health Care Interventions: Checklist and ExplanationsAnnals of Internal Medicine, 2015
- Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trialThe Lancet Oncology, 2013
- Accounting for correlation in network meta‐analysis with multi‐arm trialsResearch Synthesis Methods, 2012
- Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curvesBMC Medical Research Methodology, 2012
- Network meta-analysis of survival data with fractional polynomialsBMC Medical Research Methodology, 2011
- Checking consistency in mixed treatment comparison meta‐analysisStatistics in Medicine, 2010